FDA grants orphan drug status for Ichnos’ multiple myeloma antibody

10 Jul 2023
www.pharmaceutical-technology.com
Orphan DrugPhase 1ImmunotherapyCell Therapy
FDA grants orphan drug status for Ichnos’ multiple myeloma antibody
Preview
Source: Pharmaceutical Technology
ISB 2001 is intended for patients with multiple myeloma. Credit: David A Litman via Shutterstock.com.
The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for Ichnos Sciences’ ISB 2001 to treat patients with multiple myeloma.
ISB 2001 is a T-cell-engaging tri-specific antibody.
Recommended Reports
FDA grants orphan drug status for Ichnos’ multiple myeloma antibody
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Anetumab Corixetan in Malignant Mesothelioma GlobalData
FDA grants orphan drug status for Ichnos’ multiple myeloma antibody
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Mipasetamab Uzoptirine in Malignant Fibrous Histiocytoma GlobalData
View allCompanies IntelligenceIchnos Sciences IncView all
The company will commence a first-in-human Phase I dose-escalation, dose-expansion clinical trial of the antibody in 2023, once clearance has been given by the Australian Human Research Ethics Committee and the FDA’s approval has been received for its investigational new drug application.
ISB 2001 is the third clinical-stage asset of the company to obtain ODD status for multiple myeloma.
In March 2023, the company’s ISB 1442, a CD38 x CD47 biparatopic bispecific antibody innate cell modulator, also received ODD from the FDA.
Ichnos Sciences president and CEO Cyril Konto stated: “The FDA’s decision to grant orphan drug designation to ISB 2001 – our third clinical-stage asset to receive that designation in five years – underscores the importance of the work our team is doing to develop potentially curative therapies for the treatment of multiple myeloma.
“As new multiple myeloma diagnoses continue to climb, our charge of providing patients more innovative, novel therapies that can overcome the limitations of options available to them today becomes that much more urgent.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.